Cardiol’s Pending Phase II/III COVID-19 Trial Medically Justified and Even More Timely

Leede Jones Gable has initiated coverage on Cardiol Therapeutics Inc. (TSX:CRDL,OTCQX:CRTPF) and reported that it is medically justified for Cardiol to advance its program and to fund its Phase II/III CardiolRx trial within the next few quarters. 

Leede Jones Gable has initiated coverage on Cardiol Therapeutics Inc. (TSX:CRDL,OTCQX:CRTPF) and reported that it is medically justified for Cardiol to advance its program and to fund its Phase II/III CardiolRx trial within the next few quarters.

The recently published report on cardiovascular and inflammatory disease-focused cannabidiol developer Cardiol Therapeutics Inc. (TSX:CRDL,OTCQX:CRTPF) stated that CardiolRx is demonstrating strong cardiovascular active pharmacology with studies showing sufficient preclinical evidence to justify Cardiol’s eventual clinical programs.

“The bidirectional relationship between COVID-19 infection and cardiovascular disease is already well established and we believe it is medically justified for Cardiol to advance on this program and to preferentially fund this trial to data within the next few quarters,” said Leede Managing Director and Analyst Douglas W. Loe and Research Associate Siew Ching Yeo.

The Leede Jones Gable coverage indicated a Speculative Buy rating and with 180% projected return in consideration of CardiolRx sales into inflammatory heart disease markets, including diastolic heart failure and acute myocarditis. The drug is also expected to address the acute inflammatory response to COVID-19 infection in patients with either co-presenting or prior history of cardiovascular disease.

On September 24, 2020, Cardiol announced that the U.S. Food and Drug Administration (FDA) approved the Company’s Investigational New Drug (IND) application to commence a Phase II/III, double-blind, a placebo-controlled clinical trial investigating the efficacy and safety of CardiolRx™, a pharmaceutically produced extra-strength cannabidiol formulation, in 422 hospitalized COVID-19 patients with a prior history of, or risk factors for, cardiovascular disease (CVD). The trial will take place at major centers in the United States, where the prevalence of COVID-19 remains high.

Read the full report here.

Featured
Le 29 septembreSeptember 2021) Love Pharma Inc., the issuer resulting from a Fundamental Change of Glenbriar Technologies Inc. has been approved for listing. Listing and disclosure documents will be available at on the trading date. Love Pharma Inc., is a specialized health and wellness company offering pharmaceutical and therapeutic products with proven technologies for which it has the exclusive rights to produce, ...

Le 29 septembreSeptember 2021) Love Pharma Inc., the issuer resulting from a Fundamental Change of Glenbriar Technologies Inc. (GTI.X), has been approved for listing.

Listing and disclosure documents will be available at www.thecse.com on the trading date.

read more Show less

How to Invest in Life Science

How to Invest in Life Science

A breakdown of everything to know about how to invest in life science — from biotech and pharmaceuticals to medical devices and genetics.

The overarching term “life science” refers to the study of living organisms and life processes. Given the sector’s broad reach, many investors aren’t sure exactly how to invest in life science. 

To start, it’s important to understand that the industry encompasses the fields of biotechnology, pharmaceuticals, medical devices and genetics, to name just a few. Companies within each subsector are involved in researching and developing innovative products, advancing technology and striving towards drug or device commercialization by way of clinical trials and patent applications.

read more Show less
Sixth Wave Innovations Inc. is pleased to announce the finalization of a commercial system design for Affinity™ cannabis purification technology. SIXW is contracted to deliver three units to Oregon-based producer Green Envy Extracts after successful field trials beginning in the fall of 2021.The Affinity™ System is a leading-edge purification process that will allow cannabis producers to deliver a product with ...

Sixth Wave Innovations Inc. (CSE: SIXW) (OTCQB: SIXWF) (FSE: AHUH) ("Sixth Wave", "SIXW" or the "Company") is pleased to announce the finalization of a commercial system design for Affinity™ cannabis purification technology. SIXW is contracted to deliver three units to Oregon-based producer Green Envy Extracts (the "Customer") after successful field trials beginning in the fall of 2021.

The Affinity™ System is a leading-edge purification process that will allow cannabis producers to deliver a product with the highest possible THC/cannabinoid purity with greater consistency that consumers demand. Affinity™ machines will use Sixth Wave's breakthrough nanotechnology to significantly increase yields for producers by reducing the amount of cannabis lost through traditional methods in faster times with lower costs.

read more Show less

MARKETS

Markets
TSX20762.03+297.43
TSXV910.22-7.70
DOW34639.79+617.75
S&P 5004577.10+64.06
NASD15381.32+127.27
ASX7225.20-10.70

COMMODITIES

Commodities
Gold1772.69+3.83
Silver22.42+0.05
Copper4.300.00
Palladium1783.50+8.50
Platinum945.00+9.24
Oil67.65+1.15
Heating Oil2.11+0.01
Natural Gas4.16+0.11